<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Therapeuticsmd, Inc. — News on 6ix</title>
<link>https://6ix.com/company/therapeuticsmd-inc</link>
<description>Latest news and press releases for Therapeuticsmd, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/therapeuticsmd-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cf2178dffbe2df11eba6.webp</url>
<title>Therapeuticsmd, Inc.</title>
<link>https://6ix.com/company/therapeuticsmd-inc</link>
</image>
<item>
<title>TherapeuticsMD Announces Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2025-financial-results</guid>
<pubDate>Mon, 30 Mar 2026 20:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., March 30, 2026--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025.</description>
</item>
<item>
<title>TherapeuticsMD Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2025-210500869</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2025-210500869</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 12, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025.</description>
</item>
<item>
<title>TherapeuticsMD Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2025-200500142</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2025-200500142</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., August 12, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025.</description>
</item>
<item>
<title>TherapeuticsMD Announces First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2025-200500977</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2025-200500977</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., May 13, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025.</description>
</item>
<item>
<title>TherapeuticsMD Announces Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-2024-financial-200500002</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-2024-financial-200500002</guid>
<pubDate>Thu, 27 Mar 2025 20:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., March 27, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024.</description>
</item>
<item>
<title>TherapeuticsMD Announces Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2024-financial-results</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Announces Second Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2024-financial-results</guid>
<pubDate>Mon, 12 Aug 2024 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Announces First Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2024-financial-results</guid>
<pubDate>Fri, 10 May 2024 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Announces Full Year 2023 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2023-financial-results</guid>
<pubDate>Fri, 29 Mar 2024 04:00:00 GMT</pubDate>
<description>• Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD),</description>
</item>
<item>
<title>TherapeuticsMD Announces Third Quarter 2023 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2023-financial-results</guid>
<pubDate>Tue, 14 Nov 2023 05:00:00 GMT</pubDate>
<description>Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives BOCA RATON, Fla.--(BUSINESS</description>
</item>
<item>
<title>TherapeuticsMD Announces Second Quarter 2023 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2023-financial-results</guid>
<pubDate>Mon, 14 Aug 2023 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Announces First Quarter 2023 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2023-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-first-quarter-2023-financial-results</guid>
<pubDate>Mon, 15 May 2023 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2022-financial-results-and-provides-update-on-business-model-transition</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-full-year-2022-financial-results-and-provides-update-on-business-model-transition</guid>
<pubDate>Fri, 07 Apr 2023 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical</description>
</item>
<item>
<title>TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-completes-transaction-to-license-its-products-to-mayne-pharma</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-completes-transaction-to-license-its-products-to-mayne-pharma</guid>
<pubDate>Tue, 03 Jan 2023 05:00:00 GMT</pubDate>
<description>- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD’s products and acquires certain assets - - TXMD received approximately $153.1 million</description>
</item>
<item>
<title>TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-definitive-agreements-to-license-its-products-to-mayne-pharma</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-definitive-agreements-to-license-its-products-to-mayne-pharma</guid>
<pubDate>Sun, 04 Dec 2022 05:00:00 GMT</pubDate>
<description>- TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to</description>
</item>
<item>
<title>TherapeuticsMD Announces Third Quarter 2022 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-third-quarter-2022-financial-results</guid>
<pubDate>Mon, 14 Nov 2022 05:00:00 GMT</pubDate>
<description>- Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - BOCA RATON,</description>
</item>
<item>
<title>TherapeuticsMD Announces Additional $7 Million Private Placement</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-additional-dollar7-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-additional-dollar7-million-private-placement</guid>
<pubDate>Mon, 31 Oct 2022 04:00:00 GMT</pubDate>
<description>Maturity Date of Financing Agreement Extended to November 30, 2022 BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD”</description>
</item>
<item>
<title>TherapeuticsMD Announces $7 Million Private Placement</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-dollar7-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-dollar7-million-private-placement</guid>
<pubDate>Mon, 03 Oct 2022 04:00:00 GMT</pubDate>
<description>Maturity Date of Financing Agreement Extended to October 31, 2022, with the Ability to Extend to November 30, 2022, if Additional Capital is Raised BOCA</description>
</item>
<item>
<title>TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-appoints-dr-brian-bernick-and-mr-mark-glickman-as-interim-co-chief-executive-officers</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-appoints-dr-brian-bernick-and-mr-mark-glickman-as-interim-co-chief-executive-officers</guid>
<pubDate>Mon, 12 Sep 2022 04:00:00 GMT</pubDate>
<description>- Robust Strategic Alternatives Process Continues - BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the</description>
</item>
<item>
<title>TherapeuticsMD Announces Second Quarter 2022 Financial Results</title>
<link>https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2022-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/therapeuticsmd-inc/news/therapeuticsmd-announces-second-quarter-2022-financial-results</guid>
<pubDate>Mon, 15 Aug 2022 04:00:00 GMT</pubDate>
<description>- Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET</description>
</item>
</channel>
</rss>